Literature DB >> 8938104

Neutropenia in X-linked agammaglobulinemia.

J E Farrar1, J Rohrer, M E Conley.   

Abstract

X-linked agammaglobulinemia (XLA) is usually considered a disorder of B cell development; however, the gene that is defective in XLA encodes a cytoplasmic tyrosine kinase called Btk, that is expressed throughout myeloid as well as B cell differentiation. A review of medical records of patients in whom mutations in Btk had been identified indicated that 13 of 50 patients (26%) had experienced episodes of profound neutropenia. In 12 of the 13 patients, neutropenia was part of the acute illness that precipitated an evaluation for immunodeficiency. These boys were more likely to be less than a year of age at the time of diagnosis and they were less likely to have a family history of immunodeficiency. Neutropenia was associated with staphylococcal or pseudomonas sepsis in 6 of the patients. The duration of neutropenia was variable but was often more than 1 week. Neutropenia was not seen in any patient with XLA receiving intravenous gammaglobulin. Although neutropenia was not associated with any specific mutation in Btk, most of the alterations in this gene in the patients with XLA and neutropenia resulted in the absence of Btk protein or in amino acid substitutions in sites thought to be critical to Btk function. Btk may not be required for neutrophil production under normal circumstances; however, it may play a role in the response to stress.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938104     DOI: 10.1006/clin.1996.0188

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  24 in total

Review 1.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 2.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 3.  Neutrophil disorders and their management.

Authors:  R Lakshman; A Finn
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

4.  Pseudomonas aeruginosa sepsis and ecthyma gangrenosum as initial manifestations of primary immunodeficiency.

Authors:  María Baro; Miguel Angel Marín; Jesús Ruiz-Contreras; Sira Fernandez de Miguel; Ignacio Sánchez-Díaz
Journal:  Eur J Pediatr       Date:  2003-12-20       Impact factor: 3.183

Review 5.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 6.  Immunity to microbes: lessons from primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Antonio Coutinho
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

Review 7.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

8.  Three brothers of X-linked agammaglobulinemia: the relation between phenotype and neutropenia.

Authors:  Chihiro Kawakami; Akiko Inoue; Maki Koh; Kimitaka Takitani; Hirokazu Kanegane; Toshio Miyawaki; Hiroshi Tamai
Journal:  Int J Hematol       Date:  2009-06-17       Impact factor: 2.490

9.  Clinical and molecular analysis of patients with defects in micro heavy chain gene.

Authors:  Eduardo Lopez Granados; Andrea S Porpiglia; Mary Beth Hogan; Nuria Matamoros; Silvia Krasovec; Claudio Pignata; C I E Smith; Lennart Hammarstrom; Janne Bjorkander; Bernd H Belohradsky; G Fontan Casariego; M C Garcia Rodriguez; Mary Ellen Conley
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

10.  Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome.

Authors:  T P Atkinson; C A Smith; Y M Hsu; E Garber; L Su; T H Howard; J T Prchal; M P Everson; M D Cooper
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.